VBI Vaccines has published pre-clinical results of its triple candidate Covid-19 programme – VBI-2900 – and has now announced which two candidates will be progressing into Phase I/II studies.
The company is expected to advance VBI-2901, which is a a trivalent pan-coronavirus vaccine candidate against Covid-19, SARS and MERS, and VBI-2902, a monovalent vaccine targeting SARS-CoV-2, the virus which causes Covid-19, into clinical trials by the end of 2020. VBI believes they have the potential to be single dose vaccines.
Go deeper with GlobalData
VBI president and CEO Jeff Baxter commented: “We are excited to announce these impressive pre-clinical data, which we believe clearly support the advancement of the two vaccine candidates, VBI-2901 and VBI-2902, into human clinical studies around the end of the year.
“An effective solution to the ongoing Covid-19 pandemic will require a vaccine that is capable of providing robust protection, quickly.
“Based on the data seen to-date, we believe the VBI-2900 program has the potential to be administered as a one-dose vaccine regimen at human doses ranging from 2-5mcg, and, further, VBI-2901 may offer increased breadth of reactivity across a broader range of coronaviruses.
“We are very encouraged by these results and remain deeply committed to addressing this devastating public health crisis.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataVBI has been collaborating with the National Research Council of Canada on a pan coronavirus vaccine since April. The company’s subsidiary Variation BioTechnologies has also received CAD$56m from the Canadian government to support the VBI-2900 programme.
